Preparation and in vitro studies of [125I]IUDR-T101 antibody conjugate. Academic Article uri icon

Overview

abstract

  • Idoxuridine labeled with 125I was conjugated to polylysine. This conjugate was then coupled to the carbohydrate side chains of T101 monoclonal antibody (anti-CD5). The immunoreactivity, cell retention, cytotoxicity, and intracellular localization of this conjugate was tested in CCRF-CEM cells (CD5 positive). The conjugate had 68% immunoreactivity. The retention of 125I by CCRF-CEM cells was higher for the conjugate than for T101 directly labeled with 125I and more of it localized in the nucleus than did the 125I-labeled T101. The 125I IUDR-polylysine-T101 conjugate was more cytotoxic than the 125I-labeled T101. In conclusion, the conjugation of [125I]IUDR to T101 is feasible, and preferential targeting of the 125I to the nucleus is obtained.

publication date

  • April 1, 1999

Research

keywords

  • Idoxuridine
  • Immunoconjugates
  • Iodine Radioisotopes
  • T-Lymphocytes

Identity

Scopus Document Identifier

  • 0032933273

Digital Object Identifier (DOI)

  • 10.1089/cbr.1999.14.91

PubMed ID

  • 10850292

Additional Document Info

volume

  • 14

issue

  • 2